HOUSE_OVERSIGHT_024020.jpg

number of commercial stage companies with novel and clearly differentiated products targeting defined and established high growth market segments.

DEAL FLOW AND INVESTMENT PROCESS
The Fund Managers have a proactive approach to deal sourcing, which targets both private and public opportunities. The established and proven sourcing activities rely on diverse networks of deal sources that have been built and cultivated over two decades and focus on identifying compelling healthcare technology investment opportunities, at attractive time points for investment. These efforts balance the inherent attractiveness of an innovative technology with the selection of the appropriate investment stage, offering an optimal risk-adjusted return potential and multiple paths to realization and liquidity.

The Fund Managers have refined and successfully executed this investment process over many years, and it is an integral part of the firm’s culture. New Leaf’s investment philosophy and process emphasize a team approach to maximizing investment returns, focusing the most appropriate resources within the firm to deal sourcing, rigorous investment analysis, deep involvement with portfolio companies and active management of financings and exits.

DISTINCTIVE FEATURES OF NEW LEAF
Over the last two decades, New Leaf has established itself as one of the premier brands in healthcare technology investing as a result of a powerful combination of:

• one of the most established and stable teams in the venture capital industry with deep and complementary operating and investing experience;

• a long term track record across portfolios of healthcare technology investments in six distinct venture funds and over $1.6 billion in total invested capital that has demonstrated consistent outperformance versus venture industry peers and relevant public market indices (S&P 500, S&P Healthcare, NASDAQ Composite, and Russell 3000)14;

• an evolving investment strategy, focused on a diversified portfolio of investments across sectors, stages (start-ups to growth equity), and therapeutic areas that has proven to generate returns through both up and down phases of macro investment cycles;

• a hands-on approach to working with management teams as board members to optimize corporate strategy, develop and refine clinical, regulatory, and operating plans, recruit world-class talent, and drive business development activities that lead to value-maximizing follow-on financings, partnerships, and M&A transactions; and

• a reputation for intellectual rigor, hard work, value added contributions, and constructive collaboration that makes New Leaf a sought after lead investor by outstanding entrepreneurs and a preferred co-investor amongst a broad range of top quality investors.

14 Please refer to Section III: “Summary of Historical Investment Performance” and Section XIII: “Appendices” including endnotes B, C, F and G in Appendix 4.

9
CONTROL NUMBER 257 - CONFIDENTIAL
HOUSE_OVERSIGHT_024020